Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468463 | 0.83 | KDM4E (0.34) | ALDH1A1HPGD | |
| SCHEMBL30241145 | 0.76 | CA12 (0.44) | ALDH1A1HPGDCA12CA2CA9 | |
| SCHEMBL18595012 | 0.75 | ALDH1A1 (0.30) | ALDH1A1HPGDCA12CA2CA9 | |
| SCHEMBL30295345 | 0.73 | AKR1B1 (0.44) | ALDH1A1 | |
| SCHEMBL14927150 | 0.71 | CA12 (0.40) | ALDH1A1HPGDCA12CA2CA9 | |
| SCHEMBL5080836 | 0.70 | CA12 (0.43) | ALDH1A1HPGDCA12CA2CA9 | |
| SCHEMBL4927059 | 0.70 | TDP1 (0.36) | — | |
| SCHEMBL7200816 | 0.70 | PYCR1 (0.38) | ALDH1A1HPGD | |
| SCHEMBL17666038 | 0.70 | CA12 (0.39) | ALDH1A1HPGDCA12CA2CA9 | |
| SCHEMBL3178805 | 0.69 | CA12 (0.41) | ALDH1A1CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002329-A1 | COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2021087084-A1 | COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002329-A1 | COMPOUNDS AND MODULES FOR INHIBITION OF PRE-miR-21 AND THEIR USE IN TREATMENT OF CERTAIN CANCERS | SNRPE, RPRD2, SNRPA | ALDH1A1 2557/4885HPGD 1557/4885CA12 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.